PT - JOURNAL ARTICLE AU - Fernandes-Matano, L AU - Monroy-Muñoz, IE AU - Uribe-Noguez, LA AU - Hernández-Cueto, MA AU - Sarquiz-Martínez, B AU - Pardavé-Alejandre, HD AU - Santos Coy-Arechavaleta, A AU - Alvarado-Yaah, JE AU - Rojas-Mendoza, T AU - Santacruz-Tinoco, CE AU - Grajales-Muñiz, C AU - Borja-Aburto, VH AU - Muñoz-Medina, JE TI - Weak association of coinfection by SARS-CoV-2 and other respiratory viruses with severe cases and death AID - 10.1101/2020.07.22.20159400 DP - 2020 Jan 01 TA - medRxiv PG - 2020.07.22.20159400 4099 - http://medrxiv.org/content/early/2020/07/25/2020.07.22.20159400.short 4100 - http://medrxiv.org/content/early/2020/07/25/2020.07.22.20159400.full AB - Background SARS-CoV-2 is a novel coronavirus described for the first time in China in December 2019. This virus can cause a disease that ranges in spectrum from asymptomatic to severe respiratory disease with multiorgan failure, and the most severe cases are associated with some comorbidities and patient age. However, there are patients who do not have those risk factors who still develop serious disease.Methods In this study, we identified the presence of other respiratory viruses in positive cases of COVID-19 in Mexico to determine if any coinfections were correlated with more severe manifestations of COVID-19. We analysed 103 confirmed cases of COVID-19 using RT-qPCR for the detection of 16 other respiratory viruses.Results Of the cases analysed, 14 (13.6%) were cases of coinfection, and 92% of them never required hospitalization, even when comorbidities and advanced age were involved. There weren’t significant differences between the presence of comorbidities and the mean ages of the groupsConclusions These results suggest that coinfection is not related to more severe COVID-19 and that, depending on the virus involved, it could even lead to a better prognosis. We believe that our findings may lay the groundwork for new studies aimed at determining the biological mechanism by which this phenomenon occurs and for proposing corresponding strategies to limit the progression to severe cases of COVID-19.CLINICAL TRIAL REGISTRATION Not applyCompeting Interest StatementThe authors have declared no competing interest.Funding StatementNo external funding was received.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:División de Laboratorios de Vigilancia e Investigación Epidemiológica.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll relevant data are within the paper and the information is supported by supplementary files that can be consulted with the corresponding author.